Next-Generation synthetic cannabinoid therapeutics
Seite 1 von 2 Neuester Beitrag: 09.06.22 21:41 | ||||
Eröffnet am: | 04.08.16 07:37 | von: chinasky | Anzahl Beiträge: | 27 |
Neuester Beitrag: | 09.06.22 21:41 | von: wallander | Leser gesamt: | 12.506 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < | 2 > |
Zynerba gab bekannt, dass die ersten Patienten der Gesellschaft mit einer Phase 2 der klinischen Studie begonnen haben. Es handelt sich hierbei um eine randomisierte, multizentrische , Studie für Mehrfachdosis. Hierbei soll das entwickelte ZYN002 Cannabidiol ( CBD) Gel , zur Behandlung von Epilepsie bei Erwachsenen bewertet werden. Patienten mit refraktären fokalen Anfällen bei der Behandlung von Epilepsie , Osteoarthritis (OA) und Fragile -X-Syndrom ( FXS) mti ZYN002 CBD-Gel (das erste und einzige synthetische CBD) zur transdermalen Verabreichung.
Original Mitteilung/Zitat:"DEVON, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the first patients have been dosed in the Company’s Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, a randomized, multi-center, multi-dose study to evaluate ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. ZYN002 CBD gel is the first and only synthetic CBD formulated as a permeation-enhanced gel for transdermal delivery and is in development for the treatment of epilepsy, osteoarthritis (OA) and Fragile X syndrome (FXS)." ENDE Zitat
Source:http://www.stockwatch.com/News/...160801&symbol=ZYNE®ion=U
Source:http://marijuanaindex.com/industry-news-item/?newsId=8433640198110081
Company: http://zynerba.com/about-us-2/
Source:http://marijuanaindex.com/industry-news-item/?newsId=8066544143041055
Quelle/Chart:http://stockcharts.com/h-sc/ui?s=ZYNE
Source:http://www.otcmarkets.com/stock/ZYNE/news
Zitat:"On Dec. 14, 2016, the United States Drug Enforcement Administration announced a new rule that makes hemp-based cannabidiol a federally illegal substance. Under the new rules, liquid extracts derived from plants of the cannabis genus that contain one or more cannabinoids are now considered a schedule I substance.....Introduced by DEA chief Chuck Rosenberg under the auspices of allowing “DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana,” the new rule has many advocates crying foul over its overly broad interpretation.....
“What DEA Administrator Rosenberg seems to be saying with this clarification is: You may be able to grow hemp. But if you try to extract CBD oil from it, the DEA considers that a federal crime,” ENDE Zitat
Source:http://mjinews.com/dea-issues-new-rule-to-ban-cannabidiol/
Source:http://www.stockwatch.com/News/...170209&symbol=ZYNE®ion=U
http://zynerba.com/...nnounces-proposed-public-offering-common-stock/
Jenrin Discovery, Inc., privately-held US , owns 9 US patents + 3 pending
Cara Therapeutics Inc. (NASDAQ: CARA) owns 9 US patents
GW Pharmaceuticals Limited (NASDAQ: GWPH), owns 8 issued patents + 22 pending
Full Spectrum Laboratories Ltd, subsidiary of Teewinot Life Sciences Corporation, owns 5 US patents + 5 pending
Insys Therapeutics, Inc. (NASDAQ: INSY) , owns 4 US patents + 4 pending
Arena Pharmaceuticals Inc. (NASDAQ: ARNA)owns 1 US patent + 2 pending
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) owns 1 US patents + 1 pending
Axim Biotechnologies, Inc. (OTCMKTS: AXIM) owns 5 pending, published US patent applications
Echo Pharmaceuticals B.V., privately-held company, owns 4 pending, published applications
Corbus Pharamaceuticals, Inc. (NASDAQ: CRBP) owns 3 pending patent applications
Biotech Institute, LLC owns 3 pending, published US patent applications
Afgin Pharma, LLC owns 3 pending, published US patent applications
United Cannabis Corp. (OTC: CNAB) owns 2 pending, published US patent application
AbbVie, Inc. owns 35 US patents + 2 pending, published US patent applications
Bristol-Myers Squibb owns 21 US patents
Sanofi-Aventis owns 9
Merck & Co. Inc. owns 3 US patents
http://patentvue.com/2017/02/01/...anies-are-rushing-to-file-patents/
Zitat:"Phase 2 data misses on primary endpoint and all other endpoints in the study
ZYN002 missing
... (automatisch gekürzt) ...
https://seekingalpha.com/article/...-indicate-major-short-opportunity
Zeitpunkt: 14.08.17 13:43
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
- neues 52 Wochen-Hoch
https://www.proactiveinvestors.com/companies/news/...-gel-219890.html
Zygel™ verfehlt primären Endpunkt und 3 sekundäre Endpunkte
https://zynerba.com/...-trial-of-zygel-cbd-gel-in-fragile-x-syndrome/
https://seekingalpha.com/news/...ynerbas-zygel-flunks-fragile-x-study
Regulatorisches Update zu Zygel™ beim Fragile X Syndrom (FXS)
Klinisch traue ich Zynerba´s CBD-Produktkandidat nicht viel zu, nachdem er in den letzten Jahren in vier Studien nicht bestehen konnte. Ich empfehle jedem sich folgenden Artikel durchzulesen und sich ggf. zu übersetzen um über die Risiken informiert zu sein.
https://endpts.com/...ther-phii-trial-all-but-ending-fragile-x-hopes/
Auf Grund der prognostizierten, relativ langen Cashreichweite bis Anfang 2023 würde ich es jedoch nicht ausschliessen, dass die Aktie von Zynerba in Richtung 6$ und drüber steigen könnte zumindest kurzfristig. Watchlist.
http://ir.zynerba.com/news-releases/...ides-regulatory-update-zygeltm